Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.568
Peer-review started: May 22, 2021
First decision: October 3, 2021
Revised: November 12, 2021
Accepted: February 15, 2022
Article in press: February 15, 2022
Published online: March 15, 2022
Processing time: 292 Days and 2.7 Hours
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations.
Core Tip: Barrett’s esophagus (BE) is an important premalignant condition. The last two decades have seen treatment paradigms increasingly shift towards endoscopic eradication therapy for dysplastic and early neoplastic cases, where it appears safe and effective. We herein provide a comprehensive review of the literature relating to Barrett’s natural history and comparative efficacy of surveillance, endoscopic and surgical therapies for BE by histological stage.